Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

CzechiaBack to Czechia

Clinical trials in Plzen – page 13

187 clinical trials in Plzen, Czechia across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

CzechiaOur site in CzechiaKlinickeTesty.cz(opens in a new tab)
Plzen at a glance
187
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

187 trials in Plzen

Open in trial search

Diabetic retinal oedema

Not recruiting

Study on the Effectiveness and Safety of OCS-01 Eye Drops with Dexamethasone for Patients with Diabetic Macular Edema

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Oculis Operations S.a.r.l.

Diffuse large B-cell lymphoma

Not recruiting

Study on Acalabrutinib with Drug Combination for Patients 75 and Older with Untreated Diffuse Large B-Cell Lymphoma

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Acerta Pharma B.V.

Cognitive disorder+1

Not recruiting

Study on RL-007 for Improving Cognitive Impairment in Schizophrenia Patients

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years
  • Substances:(2R,3S)-2-Amino-3-Hydroxy-3-Pyridin-4-Yl-1-Pyrrolidin-1-Ylpropan-1-One (2R,3R)-2,3-Dihydroxybutanedioic Acid
  • Sponsor:Recognify Life Sciences Inc.

Bronchiectasis

Not recruiting

Study on the Effects of Itepekimab for Patients with Non-Cystic Fibrosis Bronchiectasis

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Itepekimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Hidradenitis

Not recruiting

Study on Long-Term Use of Spesolimab for Patients with Hidradenitis Suppurativa Who Completed a Previous Spesolimab Study

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Spesolimab
  • Sponsor:Boehringer Ingelheim Espana S.A.

Psoriasis

Not recruiting

Study on Adjustable Brodalumab Dosage for Patients with Moderate-to-Severe Plaque Psoriasis Weighing 120 kg or More

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Brodalumab
  • Sponsor:Leo Pharma A/S

Dermatitis atopic

Not recruiting

Study on the Effectiveness and Safety of Amlitelimab for Patients Aged 12 and Older with Moderate-to-Severe Atopic Dermatitis Using Topical Corticosteroids

Registered drug
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Amlitelimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Primary biliary cholangitis

Not recruiting

Study on the Effects of Obeticholic Acid and Bezafibrate for Patients with Primary Biliary Cholangitis Who Cannot Tolerate Ursodeoxycholic Acid

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Bezafibrate
  • Sponsor:Intercept Pharmaceuticals Inc.

Chronic myeloid leukaemia

Not recruiting

Study on the Tolerability and Efficacy of Asciminib vs. Nilotinib for Adults with Newly Diagnosed Philadelphia Chromosome Positive Chronic Myeloid Leukemia

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Nilotinib
  • Sponsor:Novartis Pharma AG

Study on the Effects of NMRA-335140 for Adults with Major Depressive Disorder

Not recruiting
Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years
  • Substances:1-[6-Ethyl-8-Fluoro-4-Methyl-3-(3-Methyl-1,2,4-Oxadiazol-5-Yl)Quinolin-2-Yl]-N-(Oxan-4-Yl)Piperidin-4-Amine
  • Sponsor:Neumora Therapeutics Inc.

Study on Long-term Safety and Effectiveness of NMRA-335140 for Patients with Major Depressive Disorder

Not recruiting
InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years
  • Substances:1-[6-Ethyl-8-Fluoro-4-Methyl-3-(3-Methyl-1,2,4-Oxadiazol-5-Yl)Quinolin-2-Yl]-N-(Oxan-4-Yl)Piperidin-4-Amine
  • Sponsor:Neumora Therapeutics Inc.

Plasma cell myeloma

Not recruiting

Study Comparing Daratumumab with Drug Combination for Young Patients with Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplantation

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years
  • Substances:Bortezomib
  • Sponsor:Ceska Myelomova Skupina z.s.

Other cities in Czechia

The busiest research cities in the country

All 159 cities in Czechia

Clinical research in Plzen

What the registry says about research in the country

01 Hematologic Disorders

Groundbreaking research focusing on blood cancers and related conditions, including studies on innovative treatments for acute myeloid leukemia, chronic lymphocytic leukemia, and multiple myeloma. These trials are evaluating new therapeutic combinations and personalized treatment approaches.

  • Leukemia Treatment Studies
  • Multiple Myeloma Research
  • Myelodysplastic Syndrome Investigations
02 Respiratory Medicine

Clinical investigations targeting respiratory conditions, with particular emphasis on treatments for chronic obstructive pulmonary disease, asthma, and chronic rhinosinusitis. Research focuses on evaluating novel therapeutics and their effectiveness in managing symptoms.

  • COPD Management
  • Asthma Control Studies
  • Nasal Polyps Treatment
03 Mental Health

Innovative research addressing psychiatric disorders, including studies on generalized anxiety disorder and major depressive disorder. These trials are evaluating new therapeutic approaches and combination treatments to improve patient outcomes.

  • Anxiety Treatment Studies
  • Depression Management
  • Combination Therapy Research
Back to CzechiaAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.